某医院门诊2018-2019年第二类口服精神药品使用情况分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (459 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the way in which second category oral psychotropic drugs are used in a particular hospital.Methods Using the retrospective study method,the amounts of second category oral psychotropic drugs used and sold,defined daily doses (DDDs),daily drug cost (DDC),drug sequences ratio (B/A) and distribution between the main departments between 2018 and 2019 were analyzed.Results The variety of second category psychotropic drugs used between 2018 and 2019 was stable,and the amount of sales and constituent ratio increased stably.These drugs were mainly used by patients with cerebral,cardiovascular or psychiatric diseases.The top three drugs used were estazolam tablets,zopiclone capsules and clonazepam tablets..Estazolam tablets,zolpidem tartrate tablets and zopiclone capsules were the top three in terms of amounts of sales and DDDs.The DDC of the second category psychotropic drugs was basically stable,with tramadol hydrochloride capsules as the highest and estazolam as the lowest.The B/A of zopiclone capsules,lorazepam tablets and tramadol hydrochloride capsules was close to 1,with the B/A of estazolam tablets as the highest and that of zolpidem tartrate tablets as the lowest.Conclusions On the whole,second category oral psychotropic drugs are used rationally in this hospital.

Key words： second category psychotropic drugs sales amount defined daily doses daily drug cost rational drug use

Received: 28 May 2020

ZTFLH:	R969.3
	R971.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Defu
	WANG Lei
	YANG Bo
	GUI Haohui

Cite this article:

LIU Defu,WANG Lei,YANG Bo等. Usage of second category oral psychotropic drugs by outpatients in a hospital from 2018 to 2019[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(11): 961-963.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I11/961

[1]	国家食品药品监督管理总局.麻醉药品和精神药品管理条例国务院令第442号[S].2005.
[2]	中国药典[S].二部.北京:中国医药科技出版社.2015:88-682.
[3]	陈新谦,金有豫,汤光.新编药物学[M].18版.北京:人民卫生出版社,2018.
[4]	梁晓丽,杜燕京,吴娜,等.2012-2016年北京医院第二类精神药品使用情况统计与分析[J].临床药物治疗杂志,2017,15(9):16-20.
[5]	沈德蕾,张瑛,赵超,等.社区门诊处方苯二氮类药物人群的横断面研究 [J].中华临床医师杂志,2013,7(7):2932-2935.
[6]	伏晶琼,于庆华,陆成华.唑吡坦联合帕罗西汀治疗抑郁失眠的临床研究[J].现代药物与临床,2016,31(8):1264-1267.
[7]	王小亚.酒石酸唑吡坦片对急性脑卒中后失眠的治疗分析[J].中国医药指南,2014,12(17):161-162.
[8]	黄永涛,覃军,高旭滨,等.唑吡坦改善高原睡眠的效果及其作用机制探讨[J].中国临床研究,2015,28(5): 624-627.
[9]	黎苏,祁英杰,项婧,等.2013-2014年辽宁省肿瘤医院麻醉药品使用情况分析[J].现代药物与临床,2015,30(12):1538-1541.
[10]	牛雅娟,刘铁桥,赵敏.苯二氮类药物在特殊人群中的使用[J].中国药物滥用防治杂志,2017,23(7):196-198.